Translation control in apoptosis

Experimental Oncology

Volumn 34, Issue 3, 2012, Pages 218-230

  Liwak, U ^a,b   Faye, M D ^a,b   Holcik, M ^a,b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Bcl xL; IAP; IRES; MiRNA; p53; Selective translation

Indexed keywords

INITIATION FACTOR; INITIATION FACTOR 2ALPHA; INITIATION FACTOR 3; INITIATION FACTOR 4B; INITIATION FACTOR 4E; INITIATION FACTOR 4G; MICRORNA; PROTEIN P53; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; CELL SURVIVAL; HUMAN; NONHUMAN; REVIEW; TRANSLATION INITIATION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; CELL SURVIVAL; HUMANS; MICRORNAS; PROTEIN BIOSYNTHESIS; RIBOSOMES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872445172     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Gebauer F, Hentze MW. Molecular mechanisms of translational control. Nat Rev Mol Cell Biol 2004; 5: 827-35.
2. Rudra D, Warner JR. What better measure than ribosome synthesis? Genes Dev 2004; 18: 2431-6.
3. Holcik M, Sonenberg N. Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 2005; 6: 318-27.
4. Pelletier J, Sonenberg N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 1988; 334: 320-5.
5. Lee KA, Sonenberg N. Inactivation of cap-binding proteins accompanies the shut-off of host protein synthesis by poliovirus. Proc Natl Acad Sci USA 1982; 79: 3447-51.
6. Pestova TV, Shatsky IN, Fletcher SP, et al. A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. Genes Dev 1998; 12: 67-83.
7. Miura K, Fujibuchi W, Unno M. Splice variants in apoptotic pathway. Exp Oncol 2012; 34: 212-217.
8. Clemens MJ, Bushell M, Jeffrey IW, et al. Translation initiation factor modifications and the regulation of protein synthesis in apoptotic cells. Cell Death Differ 2000; 7: 603-15.
9. Morley SJ, McKendrick L, Bushell M. Cleavage of translation initiation factor 4G (eIF4G) during anti-Fas IgM-induced apoptosis does not require signalling through the p38 mitogen-activated protein (MAP) kinase. FEBS Lett 1998; 438: 41-8.
10. Morley SJ, Coldwell MJ, Clemens MJ. Initiation factor modifications in the preapoptotic phase. Cell Death Differ 2005; 12: 571-84.
11. Rowlands AG, Panniers R, Henshaw EC. The catalytic mechanism of guanine nucleotide exchange factor action and competitive inhibition by phosphorylated eukaryotic initiation factor 2. J Biol Chem 1988; 263: 5526-33.
12. JeffreyIW, Bushell M, Tilleray VJ, et al. Inhibition of protein synthesis in apoptosis: differential requirements by the tumor necrosis factor alpha family and a DNA-damaging agent for caspases and the double-stranded RNA-dependent protein kinase. Cancer Res 2002; 62: 2272-80.
13. Jeffrey IW, Elia A, Bornes S, et al. Interferon-alpha induces sensitization of cells to inhibition of protein synthesis by tumour necrosis factor-related apoptosis-inducing ligand. FEBS J 2006; 273: 3698-708.
14. Scheuner D, Patel R, Wang F, et al. Double-stranded RNA-dependent protein kinase phosphorylation of the alpha-subunit of eukaryotic translation initiation factor 2 mediates apoptosis. J Biol Chem 2006; 281: 21458-68.
15. Marissen WE, Guo Y, Thomas AA, et al. Identification of caspase 3-mediated cleavage and functional alteration of eukaryotic initiation factor 2alpha in apoptosis. J Biol Chem 2000; 275: 9314-23.
16. Bushell M, Wood W, Clemens MJ, Morley SJ. Changes in integrity and association of eukaryotic protein synthesis initiation factors during apoptosis. Eur J Biochem 2000; 267: 1083-91.
17. Bevilacqua E, Wang X, Majumder M, et al. eIF2alpha phosphorylation tips the balance to apoptosis during osmotic stress. J Biol Chem 2010; 285: 17098-111.
18. Warnakulasuriyarachchi D, Cerquozzi S, Cheung HH, Holcik M. Translational induction of the inhibitor of apoptosis protein HIAP2 during endoplasmic reticulum stress attenuates cell death and is mediated via an inducible internal ribosome entry site element. J Biol Chem 2004; 279: 17148-57.
19. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 1997; 16: 1909-20.
20. Raught B, Gingras A-C. Signaling to Translation Initiation. In: Translational Control in Biology and Medicine, Mathews MB, Sonenberg N, Hershey JWB (eds), Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 2007: 369-400.
21. Tee AR, Proud CG. DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling. Oncogene 2000; 19: 3021-31.
22. Tee AR, Proud CG. Staurosporine inhibits phosphorylation of translational regulators linked to mTOR. Cell Death Differ 2001; 8: 841-9.
23. Yan H, Frost P, Shi Y, et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res 2006; 66: 2305-13.
24. Proud CG. The eukaryotic initiation factor 4E-binding proteins and apoptosis. Cell Death Differ 2005; 12: 541-6.
25. Morley SJ, Coldwell MJ. Matters of Life and Death: Translation Initiation during Apoptosis. In: Translational Control in Biology and Medicine, Mathews MB, Sonenberg N, Hershey JWB (eds), Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 2007: 433-58.
26. Henis-Korenblit S, Shani G, Sines T, et al. The caspase-cleaved DAP5 protein supports internal ribosome entry site-mediated translation of death proteins. Proc Natl Acad Sci USA 2002; 99: 5400-5.
27. Nevins TA, Harder ZM, Korneluk RG, Holcik M. Distinct regulation of internal ribosome entry site-mediated translation following cellular stress is mediated by apoptotic fragments of eIF4G translation initiation factor family members eIF4GI and p97/DAP5/NAT1. J Biol Chem 2003; 278: 3572-9.
28. Hundsdoerfer P, Thoma C, Hentze MW. Eukaryotic translation initiation factor 4GI and p97 promote cellular internal ribosome entry sequence-driven translation. Proc Natl Acad Sci USA 2005; 102: 13421-6.
29. Fraser CS, Lee JY, Mayeur GL, et al. The j-subunit of human translation initiation factor eIF3 is required for the stable binding of eIF3 and its subcomplexes to 40 S ribosomal subunits in vitro. J Biol Chem 2004; 279: 8946-56.
30. Shi J, Hershey JW, Nelson MA. Phosphorylation of the eukaryotic initiation factor 3f by cyclin-dependent kinase 11 during apoptosis. FEBS Lett 2009; 583: 971-7.
31. Bushell M, Wood W, Carpenter G, et al. Disruption of the interaction of mammalian protein synthesis eukaryotic initiation factor 4B with the poly(A)-binding protein by caspase-and viral protease-mediated cleavages. J Biol Chem 2001; 276: 23922-8.
32. Shahbazian D, Parsyan A, Petroulakis E, et al. eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways. Cell Cycle 2010; 9: 4106-9.
33. Shahbazian D, Parsyan A, Petroulakis E, et al. Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. Mol Cell Biol 2010; 30: 1478-85.
34. de Almagro MC, Vucic D. The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol 2012; 34: 200-211.
35. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693-703.
36. Varfolomeev E, Blankenship JW, Wayson SM, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131: 669-81.
37. Zhao TT, Graber TE, Jordan LE, et al. hnRNP A1 regulates UV-induced NF-kappaB signalling through destabilization of cIAP1 mRNA. Cell Death Differ 2009; 16: 244-52.
38. Warnakulasuriyarachchi D, Ungureanu NH, Holcik M. The translation of an antiapoptotic protein HIAP2 is regulated by an upstream open reading frame. Cell Death Differ 2003; 10: 899-904.
39. van Eden ME, Byrd MP, Sherrill KW, Lloyd RE. Translation of cellular inhibitor of apoptosis protein 1 (c-IAP1) mRNA is IRES mediated and regulated during cell stress. RNA 2004; 10: 469-81.
40. Graber TE, Baird SD, Kao PN, et al. NF45 functions as an IRES trans-acting factor that is required for translation of cIAP1 during the unfolded protein response. Cell Death Differ 2010; 17: 719-29.
41. Yoshimura FK, Luo X, Zhao X, et al. Up-regulation of a cellular protein at the translational level by a retrovirus. Proc Natl Acad Sci USA 2008; 105: 5543-8.
42. Lewis SM, Cerquozzi S, Graber TE, et al. The eIF4G homolog DAP5/p97 supports the translation of select mRNAs during endoplasmic reticulum stress. Nucleic Acids Res 2008; 36: 168-78.
43. Corthesy B, Kao PN. Purification by DNA affinity chromatography of two polypeptides that contact the NF-AT DNA binding site in the interleukin 2 promoter. J Biol Chem 1994; 269: 20682-90.
44. Kiesler P, Haynes PA, Shi L, et al. NF45 and NF90 regulate HS4-dependent interleukin-13 transcription in T cells. J Biol Chem 2010; 285: 8256-67.
45. Merrill MK, Gromeier M. The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site. J Virol 2006; 80: 6936-42.
46. Sakamoto S, Aoki K, Higuchi T, et al. The NF90-NF45 complex functions as a negative regulator in the microRNA processing pathway. Mol Cell Biol 2009; 29: 3754-69.
47. Shamanna RA, Hoque M, Lewis-Antes A, et al. The NF90/NF45 complex participates in DNA break repair via nonhomologous end joining. Mol Cell Biol 2011; 31: 4832-43.
48. Arora V, Cheung HH, Plenchette S, et al. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem 2007; 282: 26202-9.
49. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14: 5000-5.
50. Cartier J, Berthelet J, Marivin A, et al. Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription. J Biol Chem 2011; 286: 26406-17.
51. LaCasse EC, Mahoney DJ, Cheung HH, et al. IAP-targeted therapies for cancer. Oncogene 2008; 27: 6252-75.
52. Holcik M, Lefebvre C, Yeh C, et al. A new internal-ribosome-entry-site motif potentiates XIAP-mediated cytoprotection. Nat Cell Biol 1999; 1: 190-2.
53. Riley A, Jordan LE, Holcik M. Distinct 5' UTRs regulate XIAP expression under normal growth conditions and during cellular stress. Nucleic Acids Res 2010; 38: 4665-74.
54. Baird SD, Lewis SM, Turcotte M, Holcik M. A search for structurally similar cellular internal ribosome entry sites. Nucleic Acids Res 2007; 35: 4664-77.
55. Holcik M, Korneluk RG. Functional characterization of the X-linked inhibitor of apoptosis (XIAP) internal ribosome entry site element: role of La autoantigen in XIAP translation. Mol Cell Biol 2000; 20: 4648-57.
56. Holcik M, Gordon BW, Korneluk RG. The internal ribosome entry site-mediated translation of antiapoptotic protein XIAP is modulated by the heterogeneous nuclear ribonucleoproteins C1 and C2. Mol Cell Biol 2003; 23: 280-8.
57. Durie D, Lewis SM, Liwak U, et al. RNA-binding protein HuR mediates cytoprotection through stimulation of XIAP translation. Oncogene 2011; 30: 1460-9.
58. Lewis SM, Veyrier A, Hosszu Ungureanu N, et al. Subcellular relocalization of a trans-acting factor regulates XIAP IRES-dependent translation. Mol Biol Cell 2007; 18: 1302-11.
59. Liwak U, Thakor N, Jordan LE, et al. Tumor suppressor PDCD4 represses internal ribosome entry site-mediated translation of antiapoptotic proteins and is regulated by S6 kinase 2. Mol Cell Biol 2012; 32: 1818-29.
60. Allemand E, Guil S, Myers M, et al. Regulation of heterogenous nuclear ribonucleoprotein A1 transport by phosphorylation in cells stressed by osmotic shock. Proc Natl Acad Sci USA 2005; 102: 3605-10.
61. Gu L, Zhu N, Zhang H, et al. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell 2009; 15: 363-75.
62. Fridman JS, Hernando E, Hemann MT, et al. Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res 2003; 63: 5703-6.
63. Pardo OE, Wellbrock C, Khanzada UK, et al. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J 2006; 25: 3078-88.
64. Qian B, Katsaros D, Lu L, et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat 2009; 117: 131-40.
65. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
66. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31.
67. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-10.
68. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-9.
69. Halaby MJ, Yang DQ. p53 translational control: a new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics. Gene 2007; 395: 1-7.
70. Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
71. Yang DQ, Halaby MJ, Zhang Y. The identification of an internal ribosomal entry site in the 5'-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage. Oncogene 2006; 25: 4613-9.
72. Fu L, Benchimol S. Participation of the human p53 3′UTR in translational repression and activation following gamma-irradiation. EMBO J 1997; 16: 4117-25.
73. Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 2005; 123: 49-63.
74. Mazan-Mamczarz K, Galban S, Lopez de Silanes I, et al. RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc Natl Acad Sci USA 2003; 100: 8354-9.
75. Candeias MM, Powell DJ, Roubalova E, et al. Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiation. Oncogene 2006; 25: 6936-47.
76. Ray PS, Grover R, Das S. Two internal ribosome entry sites mediate the translation of p53 isoforms. EMBO Rep 2006; 7: 404-10.
77. Courtois S, Verhaegh G, North S, et al. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 2002; 21: 6722-8.
78. Yin Y, Stephen CW, Luciani MG, Fahraeus R. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 2002; 4: 462-7.
79. Grover R, Ray PS, Das S. Polypyrimidine tract binding protein regulates IRES-mediated translation of p53 isoforms. Cell Cycle 2008; 7: 2189-98.
80. Christian KJ, Lang MA, Raffalli-Mathieu F. Interaction of heterogeneous nuclear ribonucleoprotein C1/C2 with a novel cis-regulatory element within p53 mRNA as a response to cytostatic drug treatment. Mol Pharmacol 2008; 73: 1558-67.
81. Kim JH, Paek KY, Choi K, et al. Heterogeneous nuclear ribonucleoprotein C modulates translation of c-myc mRNA in a cell cycle phase-dependent manner. Mol Cell Biol 2003; 23: 708-20.
82. Candeias MM, Malbert-Colas L, Powell DJ, et al. P53 mRNA controls p53 activity by managing Mdm2 functions. Nat Cell Biol 2008; 10: 1098-105.
83. Grover R, Sharathchandra A, Ponnuswamy A, et al. Effect of mutations on the p53 IRES RNA structure: implications for de-regulation of the synthesis of p53 isoforms. RNA Biol 2011; 8: 132-42.
84. Bellodi C, Kopmar N, Ruggero D. Deregulation of oncogene-induced senescence and p53 translational control in X-linked dyskeratosis congenita. EMBO J 2010; 29: 1865-76.
85. Ruggero D, Grisendi S, Piazza F, et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 2003; 299: 259-62.
86. Yoon A, Peng G, Brandenburger Y, et al. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 2006; 312: 902-6.
87. Serrano M, Lin AW, McCurrach ME, et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593-602.
88. Montanaro L, Calienni M, Bertoni S, et al. Novel dyskerin-mediated mechanism of p53 inactivation through defective mRNA translation. Cancer Res 2010; 70: 4767-77.
89. Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol 2012; 19: 586-93.
90. Lee Y, Jeon K, Lee JT, et al. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 2002; 21: 4663-70.
91. Gregory RI, Yan KP, Amuthan G, et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004; 432: 235-40.
92. Lund E, Guttinger S, Calado A, et al. Nuclear export of microRNA precursors. Science 2004; 303: 95-8.
93. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005; 123: 631-40.
94. Eulalio A, Huntzinger E, Nishihara T, et al. Deadenylation is a widespread effect of miRNA regulation. RNA 2009; 15: 21-32.
95. Piao X, Zhang X, Wu L, Belasco JG. CCR4-NOT deadenylates mRNA associated with RNA-induced silencing complexes in human cells. Mol Cell Biol 2010; 30: 1486-94.
96. Meister G, Landthaler M, Patkaniowska A, et al. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell 2004; 15: 185-97.
97. Maroney PA, Yu Y, Fisher J, Nilsen TW. Evidence that microRNAs are associated with translating messenger RNAs in human cells. Nat Struct Mol Biol 2006; 13: 1102-7.
98. Petersen CP, Bordeleau ME, Pelletier J, Sharp PA. Short RNAs repress translation after initiation in mammalian cells. Mol Cell 2006; 21: 533-42.
99. Humphreys DT, Westman BJ, Martin DI, Preiss T. MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function. Proc Natl Acad Sci USA 2005; 102: 16961-6.
100. Pillai RS, Bhattacharyya SN, Artus CG, et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 2005; 309: 1573-6.
101. Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol 2005; 7: 719-23.
102. Eulalio A, Behm-Ansmant I, Schweizer D, Izaurralde E. P-body formation is a consequence, not the cause, of RNA-mediated gene silencing. Mol Cell Biol 2007; 27: 3970-81.
103. Bhattacharyya SN, Habermacher R, Martine U, et al. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell 2006; 125: 1111-24.
104. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
105. Suzuki HI, Yamagata K, Sugimoto K, et al. Modulation of microRNA processing by p53. Nature 2009; 460: 529-33.
106. Wang Y, Lee CG. MicroRNA and cancer-focus on apoptosis. J Cell Mol Med 2009; 13: 12-23.
107. Babashah S, Soleimani M. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer 2011; 47: 1127-37.
108. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65: 6029-33.
109. Pan X, Wang ZX, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther 2011; 10: 1224-32.
110. Jansen AP, Camalier CE, Stark C, Colburn NH. Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther 2004; 3: 103-10.
111. Yang HS, Knies JL, Stark C, Colburn NH. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene 2003; 22: 3712-20.
112. Dorrello NV, Peschiaroli A, Guardavaccaro D, et al. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006; 314: 467-71.
113. LaRonde-LeBlanc N, Santhanam AN, Baker AR, et al. Structural basis for inhibition of translation by the tumor suppressor Pdcd4. Mol Cell Biol 2007; 27: 147-56.
114. Suzuki C, Garces RG, Edmonds KA, et al. PDCD4 inhibits translation initiation by binding to eIF4A using both its MA3 domains. Proc Natl Acad Sci USA 2008; 105: 3274-9.
115. Singh P, Wedeken L, Waters LC, et al. Pdcd4 directly binds the coding region of c-myb mRNA and suppresses its translation. Oncogene 2011; 30: 4864-73.
116. Wedeken L, Singh P, Klempnauer KH. Tumor suppressor protein Pdcd4 inhibits translation of p53 mRNA. J Biol Chem 2011; 286: 42855-62.
117. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-9.
118. Bottoni A, Piccin D, Tagliati F, et al. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol 2005; 204: 280-5.
119. Porkka KP, Pfeiffer MJ, Waltering KK, et al. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67: 6130-5.
120. Matskevich AA, Moelling K. Stimuli-dependent cleavage of Dicer during apoptosis. Biochem J 2008; 412: 527-34.
121. Nakagawa A, Shi Y, Kage-Nakadai E, et al. Caspase-dependent conversion of Dicer ribonuclease into a death-promoting deoxyribonuclease. Science 2010; 328: 327-34.
122. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
123. Holcik M, Sonenberg N, Korneluk RG. Internal ribosome initiation of translation and the control of cell death. Trends Genet 2000; 16: 469-73.